In the news release, AtheroNova Adds New Medical Advisor, issued
April 15, 2013 by AtheroNova Inc.
over PR Newswire, we are advised by the company that updates have
been made. The complete, corrected release follows:
Noted Atherosclerosis Researcher Joins AtheroNova Team Dr. John
Kastelein Appointed Co-Principal Investigator
IRVINE, Calif., April 15, 2013 /PRNewswire/ -- AtheroNova Inc.
(OTCBB: AHRO), a biotech company focused on the research and
development of compounds to safely regress atherosclerotic plaque
and improve lipid profiles in humans, today announced that
John J.P. Kastelein, MD, PhD,
Professor of Medicine at the Department of Vascular Medicine at the
Academic Medical Center and Strategic Chair of Genetics in
Cardiovascular Disease at the University of Amsterdam, has joined the Company as a member
of the Medical Advisory Board and will be a Co-Principal
Investigator in the Company's upcoming clinical trials.
"We are pleased to announce that Dr. Kastelein has joined
AtheroNova in this very important advisory role as we continue to
expand our scientific and medical teams essential for transition to
a clinical stage company," stated Thomas W.
Gardner, CEO of AtheroNova. "Dr. Kastelein's leadership in
the area of lipidology and his Lipid Research Clinic in
Amsterdam has been an integral
part of many atherogenesis studies including IDEAL, TNT, CAPTIVATE,
ENHANCE, ILLUMINATE, JUPITER and RADIANCE. We feel that
adding Dr. Kastelein to the AtheroNova team is significant in its
impact on the knowledge he will contribute to our clinical
efforts."
"Professor Kastelein is world renowned for his cutting edge
clinical care of cardiovascular patients and for his pioneering
clinical research activities that have contributed to a very
significant reduction in the ravages of cardiovascular disease in
this decade," commented Mark K.
Wedel, M.D., Chief Medical Officer of AtheroNova. "We
are honored that John will be bringing his talents and leadership
to AtheroNova's efforts to further improve the plight of
cardiovascular patients."
"I was initially attracted to AtheroNova by the team that they
are building, including my colleagues Dr. Mark Wedel and Dr. Steve
Nicholls," remarked Dr. Kastelein. "AtheroNova's
science, though early-stage, has a chance to become an important
part of the treatment of cardiovascular disease. I am looking
forward to building on the research success of AHRO-001 and the
opportunity to evaluate the drug in clinical trials."
Dr. Kastelein is Professor of Medicine at the Department of
Vascular Medicine at the Academic Medical Center (AMC) of the
University of Amsterdam, where he
holds the Strategic Chair of Genetics of Cardiovascular
Disease. He founded the Lipid Research Clinic at the Academic
Medical Centre in Amsterdam in
1989 which has become part of the department of Vascular
Medicine. Last year he received the Lifetime Achievement
Award of the Dutch Heart Foundation and awarded a CVON grant.
He was president of the Dutch Atherosclerosis Society (DAS) until
2009 and chairs the National Scientific Committee on Familial
Hypercholesterolemia (EHC). He also is a member of the Royal Dutch
Society for Medicine & Physics, the Council for Basic Science
of the American Heart Association and the European Atherosclerosis
Society. He also is a board member of the International Task Force
for CHD Prevention and was recently appointed to the Executive
Board of the International Atherosclerosis Society (IAS) and Fellow
of the European Society of Cardiology.
Dr. Kastelein's current research interests can be found in the
etiology, diagnosis, prevention and treatment of
hypertriglyceridemia, hypercholesterolemia and low HDL cholesterol,
all conditions associated with atherosclerosis and cardiovascular
disease. He has published over 700 research papers in peer
reviewed journals, including Nature Genetics, Lancet, New England
Journal of Medicine, JAMA and Circulation.
Besides the scientific programs aimed at the etiology of
atherogenesis, Dr. Kastelein also serves on a number of executive
and steering committees of large intervention studies, including
the IDEAL, TNT, CAPTIVATE, ENHANCE, ILLUMINATE, JUPITER, RADIANCE
and numerous others of which TNT (2005), RADIANCE 1 (2007), ENHANCE
(2008) and JUPITER (2008) are published in the New England Journal
of Medicine, IDEAL (2006) in JAMA and RADIANCE 2 (2007) in Lancet.
He also serves as an International Associate Editor of the European
Heart Journal.
Dr. Kastelein was also one of the founders of Amsterdam
Molecular Therapeutics Inc. (AMT), a gene therapy company based on
the concept of gene replacement in hereditary lipoprotein
disorders. AMT was a successful Initial Public Offering (IPO) at
EuroNext in Amsterdam in 2007. The
results of the first successful human gene therapy trial were
widely publicized in the media and were published in ATVB in
2008. Furthermore, this gene therapy (Glybera) has now been
approved by the European commission and constitutes the first
approved gene therapy worldwide. Dr. Kastelein also founded
Dezima Inc., a company that develops assets for the treatment of
dyslipidemia and is currently developing TA-8995, a CETP
inhibitor. In 1995, Dr. Kastelein set up a foundation for the
active identification of patients with classical familial
hypercholesterolemia (FH) in the
Netherlands (StoeH), for which he currently holds a position
in the board of directors. This program has now been fully
institutionalized and is financially supported by the Ministry of
Health with a total grant of approximately 30 million Euros. Since its inception, the StoeH
has found over 27,000 individuals for whom a molecular diagnosis of
FH could be made. The subsequent improvement of the treatment of
these FH carriers has saved many lives, as published in Lancet in
2001 and very recently in the British Medical Journal in
2008. In 1997 and 1998 while serving as a visiting Professor
at the Center for Molecular Medicine and Therapeutics at the
University of British Columbia,
Vancouver, Canada, Dr. Kastelein
was a co-founder of Xenon Genetics Inc., a drug discovery company
(now Xenon Pharmaceuticals Inc.) based in Vancouver, Canada.
He received his medical degree in Amsterdam in 1980 where he subsequently
received specialty training in internal medicine. Then, between
1986 and 1988, he was trained in medical genetics, lipidology and
molecular biology at the University of British
Columbia, Vancouver under
the guidance of Prof. Dr. M.R.
Hayden.
About AtheroNova
AtheroNova Inc., through its wholly-owned subsidiary, AtheroNova
Operations, Inc., is a biotechnology company focused on the
discovery, research, development and licensing of novel compounds
to reduce or regress atherosclerotic plaque deposits and to safely
improve lipid profiles in humans. In addition to its lead compound
AHRO-001, AtheroNova plans to develop multiple applications for its
patents-pending therapies in market sectors that include:
Cardiovascular Disease, Stroke, Peripheral Artery Disease, Dementia
and Alzheimer's and Erectile Dysfunction, all of which have been
linked to atherosclerosis. Atherosclerosis and its related
pharmaceutical expenses for these indications cost consumers more
than $41 billion annually in
the United States alone. For more
information, please visit www.AtheroNova.com.
Forward-Looking Statements
This news release includes "forward-looking statements"
within the meaning of the safe harbor provisions of the United
States Private Securities Litigation Reform Act of 1995. These
statements are based upon the current beliefs and expectations of
AtheroNova's management and are subject to significant risks and
uncertainties. If underlying assumptions prove inaccurate or risks
or uncertainties materialize, actual results may differ materially
from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to,
general industry conditions and competition; significant
fluctuations in expenses associated with clinical trials, failure
to secure additional financing, the inability to complete
regulatory filings with the Food and Drug Administration,
general economic factors, including interest rate and currency
exchange rate fluctuations; the impact of pharmaceutical industry
regulation and health care legislation in the United States and internationally; global
trends toward health care cost containment; technological advances,
new products and patents attained by competitors; challenges
inherent in new product development, including obtaining regulatory
approval; AtheroNova's ability to accurately predict future market
conditions; manufacturing difficulties or delays; financial
instability of international economies and sovereign risk;
dependence on the effectiveness of AtheroNova's patents and other
protections for innovative products; and the exposure to
litigation, including patent litigation, and/or regulatory
actions.
AtheroNova undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise. Additional factors that could cause
results to differ materially from those described in the
forward-looking statements can be found in AtheroNova's 2012 Annual
Report on Form 10-K and the company's other filings with the
Securities and Exchange Commission (SEC) available at the SEC's
Internet site(www.sec.gov).
SOURCE AtheroNova Inc.